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An epidemiological modelling study to estimate the
composition of HIV-positive populations including
migrants from endemic settings
Fumiyo Nakagawa, on behalf of the Writing Group on HIV
Epidemiologic Estimates in Countries With Migrant Populations
From High Prevalence AreasM
Objective: Migrants account for a significant number of people living with HIV in
Europe, and it is important to fully consider this population in national estimates. Using
a novel approach with the UK as an example, we present key public health measures of
the HIV epidemic, taking into account both in-country infections and infections likely to
have been acquired abroad.
Design: Mathematical model calibrated to extensive data sources.
Methods: An individual-based stochastic simulation model is used to calibrate to
routinely collected surveillance data in the UK. Data on number of new HIV diagnoses,
number of deaths, CD4þ cell count at diagnosis, as well as time of arrival into the UK for
migrants and the annual number of people receiving care were used.
Results: An estimated 106 400 (90% plausibility range: 88 700–124 600) people
were living with HIV in the UK in 2013. Twenty-three percent of these people,
24 600 (15 000–36 200) were estimated to be undiagnosed; this number has
remained stable over the last decade. An estimated 32% of the total undiagnosed
population had CD4þ cell count less than 350 cells/ml in 2013. Twenty-five and 23%
of black African men and women heterosexuals living with HIV were undiagnosed
respectively.
Conclusion: We have shown a working example to characterize the HIV population in
a European context which incorporates migrants from countries with generalized
epidemics. Despite all aspects of HIV care being free and widely available to anyone
in need in the UK, there is still a substantial number of people who are not yet diagnosed
and thus not in care. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.
AIDS 2017, 31:417–425
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Introduction
It is imperative for countries to have a good under-
standing of the populations most at risk of and affected
by HIV infection, so as to inform and evaluate the
public health response to the epidemic, including the
targeting of prevention efforts and to adequately fund
treatment and healthcare services. Monitoring and
surveillance is vital to achieve this, and in combination
with modelling techniques, data generated can be used
to estimate the size of the undiagnosed and diagnosed
population as well as HIV incidence [1–5]. One major
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limitation of much modelling work, however, has been
the assumption that HIV was acquired within the
country. This is one of the reasons why estimates of
undiagnosed infections and incidence have focused
predominantly on MSM [6–8]. In the UK, where all
HIV services are provided free at the point of need,
much research estimating the extent to which HIV
affects the population has also focused predominantly on
MSM [4,5]. The number of new diagnoses in MSM
continues to rise [6] and is believed to be a result of a rise
in HIV incidence over time as well as improved testing
[5,6,9]. In contrast, the number of diagnoses of HIV
acquired through heterosexual contact has gradually
declined, mainly due to fewer diagnoses among people
born in countries with generalized HIV epidemics,
specifically sub-Saharan Africa [10]. However, this
group still constitutes the second largest proportion
of people living with HIV (PLHIV) in the UK.
Furthermore, there is some evidence that the pro-
portion of migrants with HIV who have acquired HIV
within the UK has increased [11–13].
Most estimates of key measures to describe HIV-positive
populations in the UK are derived using, but not limited
to, case-based surveillance of new diagnoses, CD4þ cell
counts at time of diagnosis and the number of deaths
in diagnosed people [1]. We have previously reported
on a method of estimation, demonstrated using data on
the HIV-positive MSM population in the UK [14].
Here, we build on this previous work and extend it to
map out the national epidemic whilst taking into
account migration of people from sub-Saharan Africa,
which is rarely considered explicitly in other back-
calculation and modelling studies [6–8]. The main aim
of this work is to demonstrate a novel approach using a
mathematical model with the UK as an example, to
present key public health outputs on the national level,
including the size of the undiagnosed population and
HIV incidence.
Methods
The model
The HIV synthesis progression model is an individual-
based stochastic simulation model of HIV progression and
the effect of antiretroviral therapy (ART). Model details
are available elsewhere [15–17]. In brief, the model aims
to simulate the course of HIV infection by following
them over time in three monthly intervals. Model
assumptions and variables are based on data from
observational cohort studies and clinical trials. Variables
modelled include the individual’s CD4þ cell count, viral
load, use of specific antiretroviral drugs, treatment
interruptions, presence of resistance mutations and
adherence levels. The risk of loss to follow-up, AIDS
events, AIDS deaths and non-AIDS deaths are
also modelled.
The model is used to simulate details for all individuals
who have lived with HIV in the UK at any time from the
beginning of the epidemic (assumed to be 1980) until
2015. For the purposes of calibrating to data from the
UK, individuals are categorized into risk groups as MSM,
black African heterosexuals and all other individuals. This
latter category includes all other heterosexual individuals,
people who inject drugs (PWID) and other less common
routes of HIV acquisition. Risk groups are not
categorized further as the main aim of this study is to
produce estimates for the PLHIV population as a whole.
The model simulates longitudinal data on people from the
time of infection. For risk groups other than black Africans,
for simplicity, individuals are assumed to have lived in the
UK at the time of infection. We also assume that some black
Africans living with HIV in the UK were likewise infected
after migration to the UK. In addition, to capture the
effects of migration to the UK of people already living with
HIV from sub-Saharan Africa, we simulate a ‘pool’ of HIV-
positive people born and living in sub-Saharan Africa
(Fig. 1). From this population, we assume a rate of
migration. This rate of arrival into the UK from the pool of
peoplewho acquired HIV in sub-Saharan Africa is assumed
to have the same trend as observed migration trends seen
for the general population [18]. In addition, we assume that
the rate of arrival would be reduced to zero (i.e. an
individual will not migrate to the UK) in the presence of
any pre-AIDS symptoms or AIDS-defining conditions. To
simulate the population pool of PLHIV in sub-Saharan
Africa, we use the HIV incidence curve from sub-Saharan
Africa based on UNAIDS estimates generated using
Spectrum/EPP [2,3] (J. Stover, Futures Institute, personal
communication).
Although HIV testing in the UK was possible from 1984
onwards [19], the possibility of diagnosis for people whilst
in sub-Saharan Africa is assumed only to be available from
1996 onwards (when testing in antenatal clinics started),
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Populaon modelled
HIV-posive people in the UK
MSM
All other individuals
Black African 
heterosexuals
HIV-posive people in 
sub-Saharan Africa
Fig. 1. The modelled population in HIV synthesis pro-
gression model, illustrating the composition of people living
with HIV in the UK, including those who have migrated from
sub-Saharan Africa.
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with the probability increasing with time. ART is
assumed to be available for people in sub-Saharan Africa
from 2000 (with scale-up from 2003 onwards) as per
WHO guidelines at the time.
Calibration to data
The model is calibrated using Approximate Bayesian
Computation (ABC) methods [20], which involves
running the simulation model multiple times, each time
sampling values for a set of input parameters from their
respective prior distributions. ABC methods are suitable
for complex simulation models in which the likelihood of
the outputs cannot be exactly calculated. It also allows us
to explore a wide parameter space and to consider
multiple sets of parameter values which are consistent
with the observed data, instead of converging to a single
set of parameter values.
For any single simulation, we define the ‘calibration-score’
to be theweighted average of thedeviances of themodelled
outputs from the observed data. Therefore, the lower the
calibration-score, the better the model fits to the data. The
calibration process is continued until at least 50 accepted
sets of parameter values are within the predefined tolerance
threshold. We chose to simulate at least 50 parameter sets
due to the trade-off between precision and run time.
Further simulations are then performed using the accepted
parameter sets, to reduce stochastic variability (i.e.
variability in model outputs between simulation runs
when using the same parameter set). We use the 50 best
fitting simulations generated in this step for our presented
results; the median, fifth and 95th percentiles of the
distribution of these model outputs are considered the
point estimate and plausibility range limits, respectively.
The main parameter values to be estimated are those
associated with the incidence (in the UK) and rate of
diagnosis. All risk groups are jointly modelled and
calibrated. Further details of the calibration method are
described in [14] and in the Supplementary material;
http://links.lww.com/QAD/B31. The model and cali-
bration method are programmed in SAS software, Version
9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Data from the HIVand AIDS reporting system, which is
the national HIV surveillance system developed and
managed by Public Health England (PHE), were used to
calibrate the model. We used case-based reports on the
number of new HIV diagnoses, number of deaths and
CD4þ cell count at diagnosis. Data collected on those
diagnosed and accessing care, such as the number seen in
care and number receiving ART, and time of arrival for
sub-Saharan African migrants were also used. The
observed data were available until 2013. Weights for
each type of data used to calculate the calibration-score
are chosen a priori to reflect perceived relative quality
and completeness. Although HIV surveillance in the UK
is based on voluntary reports from clinicians, virologists,
and public health practitioners amongst others, it is
thought to be one of the most comprehensive in the
world due to the diverse range and methods by which
information is collected and its direct link to the
commissioning of HIV services.
Results
A range of model outputs from the simulations using the
50 accepted parameter sets alongside the surveillance data
are presented in the Supplementary materials; http://
links.lww.com/QAD/B31. The following results are
based on these parameter sets which are calibrated to the
observed data in the UK.
Principal findings
The incidence of HIV, defined as the number of new
infections acquired in the UK per year, is estimated to
have remained at high levels in recent years (Fig. 2). After
the initial peak in incidence in 1980–1981 with an
average of 5400 new infections per year, it is estimated
to have steadily declined to an average of 1600 new
infections per year in the early 1990s. The incidence is
estimated to have risen to over 4500 new infections per
year since the 2000s. Between 2010 and 2013, an
estimated 4700 (90% plausibility range: 2000–9800) new
infections occurred annually. This wide plausibility range
arises because there is a time lag between individuals
acquiring HIV to then being diagnosed and reported into
the surveillance system, meaning that there are less data to
inform the incidence for later years.
By 2013, 106 400 (90% plausibility range: 88 700–
124 600) people were estimated to be living with HIV in
the UK (Fig. 3). As expected, there has been a sharper rise
in the number of PLHIV in the post-combination therapy
era due to non-zero incidence and the high effectiveness
of ART in reducing death rates.
Estimating number living with HIV in the United Kingdom Nakagawa 419
Fig. 2. Estimated incidence (number of new HIV infections
per year) in the UK by calendar year.
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The estimated total number of people living with
undiagnosed HIV in 2013 was 24 600 (90% plausibility
range: 15 000–36 200) (Fig. 3). This figure has remained
stable during the last decade. Of the 24 600 undiagnosed
population living in the UK, 32% (8000; 90% plausibility
range: 4500–12 100) are estimated to have CD4þcell
count less than 350 cells/ml and are therefore at higher
risk of progression to AIDS or clinical manifestation. We
also estimate that 95% of the undiagnosed population
have a viral load greater than 500 copies/ml.
The estimated HIV cascade of care for the UK in 2013
according to our model is shown in Fig. 4. Using our
estimate of the total number of PLHIV (100%), 77% are
diagnosed, 76% are retained in care, 68% are receiving
ART and 62% have viral load less than 50 copies/ml.
Estimates by risk group
Of the 4700 new infections which took place in the UK
each year between 2010 and 2014, we estimate that 2500
(90% plausibility range: 900–5800) were attributed to
MSM. We also estimate that 1200 (90% plausibility range:
800–2300) new infections were acquired annually in the
UK in the same period among black African
heterosexual individuals.
The rate of diagnosis, defined as the probability of being
diagnosed in the UK per year (given the person is HIV-
positive and asymptomatic), is estimated to have increased
over time to 18.9 and 15.3% respectively, for MSM and
heterosexual individuals (regardless of ethnicity or sex) for
2008 onwards (it is assumed constant over 8-year periods).
As expected, the PLHIV population size has increased in
all risk groups (Fig. 5), though the rise seems most
420 AIDS 2017, Vol 31 No 3
Fig. 3. Estimates of the total number of people living with
HIV and total number of people living with undiagnosed HIV
in the UK, by calendar year. Columns and error bars:
modelled median and 90% plausibility range.
Fig. 4. Estimated treatment cascade and population characteristics of all individuals living with HIV in the UK in 2013. Columns
and error bars: modelled median and 90% plausibility range.
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substantial among MSM. In 2013, MSM comprised the
largest share of the HIV-positive population in the UK,
approximated at 45 000 (90% plausibility range: 30 100–
53 800). The next largest groups are black African women
and black African men, with an estimated 21 900 (90%
plausibility range: 17 700–27 900) and 15 400 (90%
plausibility range: 13 700–19 100) individuals respect-
ively. Reduced migration from sub-Saharan Africa is
Estimating number living with HIV in the United Kingdom Nakagawa 421
Fig. 5. Estimates of the total number of people living with HIV and living with undiagnosed HIV by calendar year among MSM,
black African heterosexual men and women, and all other men and women. Columns and error bars: modelled median and 90%
plausibility range.
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believed to be the reason for a reduced rise in the total
number of black African heterosexual individuals living
with HIV and for the decline in the number living with
undiagnosed HIV.
The estimated size of the undiagnosed proportion in 2013
ranges from 19% (90% plausibility range: 9–28%) among
MSM, to 26% (90% plausibility range: 23–30%) and 25%
(90% plausibility range: 22–26%) in black African men
and women heterosexuals and 23% (90% plausibility
range: 17–34%) and 20% (90% plausibility range: 15–
33%) in all other men and women, respectively. The
proportion of undiagnosed people with a CD4þ cell
count less than 350 cells/ml varies greatly between risk
groups, with an estimated 27% among MSM but a
substantially higher 46% for black African heterosexuals.
Discussion
Our modelling study shows that the total number of
PLHIV in the UK in 2013 surpassed 100 000, with
around a fifth to a quarter of this population being
unaware of their infection. The model we have used has
been calibrated to a wide range of UK surveillance data,
including data on black African heterosexuals, to provide
a more detailed picture of the national epidemic than has
been done before.
There is a distinct possibility that the incidence of new
infections taking place in recent years is even greater than
the high levels seen at the beginning of the epidemic,
although there is large uncertainty associated with it. We
estimated that there were nearly 5000 new cases of HIV
occurring in the UK in 2013. This is despite the fact that
nearly two-thirds of the PLHIV population are thought
to be virally suppressed and at low risk of transmitting the
virus. Although national and international guidelines
now recommend that all PLHIV should initiate ART
[21,22], studies have shown that HIV transmission in the
UK is largely driven by the undiagnosed population and
that testing rates need to be much higher to limit further
increases in incidence [5,23]. Higher testing rates are
especially needed among black African individuals, for
which we estimate that nearly half of those undiagnosed
have CD4þ cell count less than 350 cells/ml and are in
immediate need for treatment.
Our results are in line with previous estimates published
by PHE, using the multi-parameter evidence synthesis
(MPES) method [24,25]. Like our model, the MPES
method is directly informed by surveillance data but is
combined with other data from prevalence surveys and
estimates of risk group sizes to calculate the prevalence of
HIV and the size of the undiagnosed population. The
MPES estimate for the total number of PLHIV in 2013
was 107 800 (95% credible interval: 101 600–115 800)
[10]. The plausibility range generated using our method is
considerably wider however, which is likely a result of
taking into account the uncertainty associated with
parameters which cannot be directly informed by data, as
well as the beliefs held with regards to certain items of
data (as quantified using different weights in the
calibration-score). Our method is able to complement
the information generated by the MPES method and
provides another approach to estimate the undiagnosed
population. The European Centre for Disease Prevention
and Control (ECDC) modelling tool [7,26] is also a
method based on an underlying mathematical model of
HIV which can estimate incidence and the total size of
the diagnosed and undiagnosed population; however, it
does not currently take into account migration.
To the best of our knowledge, our study is the first
modelling study done to characterize the PLHIV
population in a European context which attempts to
address and incorporate migration of individuals from
endemic settings. Migrants from sub-Saharan Africa
account for a significant proportion of cases of HIV in
Europe [27,28], and it is important to fully consider this
population in estimates and to try to disentangle the
extent to which transmission is ongoing in the European
country [29]. In settings in which a large number
of infections are thought to have occurred abroad, it is
important to know how many PLHIV actually acquired
their infection in the country of interest, to target
prevention interventions most effectively. It was used to
be considered that most migrants acquired HIV in sub-
Saharan Africa; however, more recent evidence suggests
that in fact many are now acquiring HIV post-migration
in European countries [12,30]. Here we estimated that
1200 (90% plausibility range: 800–2300) new infections
occurred annually in the UK among black African
heterosexuals in 2010–2014. In addition, although we
estimate that there has been a decline in the number of
undiagnosed black African heterosexuals, many are likely
to be diagnosed late, which means that testing is
imperative among this group.
Our estimates are based on our model being calibrated
to the date of arrival into the UK among HIV-positive
individuals from sub-Saharan Africa. These data are
not collected as part of routine case surveillance in all
countries at present; however, this field is now
recommended by the ECDC [31]. We also acknowledge
that few countries have a national cohort of all people
living with diagnosed HIV. These data are a critical part of
the model calibration.
One limitation with this modelling study was that we did
not explicitly model heterosexual individuals who are not
black African, PWID, mother-to-child-transmission cases
or other less common routes, but instead grouped them
together. This also means that we were not able to make
separate estimates of the size of these risk groups. In 2013,
PHE figures stated that 4.3% of cases of new HIV
422 AIDS 2017, Vol 31 No 3
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diagnoses were acquired through injecting drug use or
other routes of transmission (not including sexual
transmission), and there are also a small proportion of
cases without an exposure category [10]. For our risk
group-specific estimates (but not our overall estimates),
we also inherently assumed that the available data on route
of HIV transmission are correct for each individual.
Phylogenetic analyses in the UK have shown that some
self-reported heterosexual men diagnosed with HIV
could have acquired HIV through sex with other men,
choosing not to disclose sex with men at HIV diagnosis
and preferring to be identified as heterosexual [32,33].
Our main aim was to estimate the total size of the PLHIV
population, and therefore the model is more closely
calibrated to un-stratified data. This was done by
calculating the calibration-score using higher weights
for data relating to the total population compared with
risk group-specific data. Specifically, we used weights
which were twice as much because it was important that
the model outcomes were more closely calibrated to data
on the total UK population. This means our estimates
presented for the three defined groups are not as well
informed as the overall presented estimates for the UK.
For example, the point estimate of 2500 (90% plausibility
range: 900–5800) new infections among MSM per year
for 2010–2014 is lower than the estimate of 3200 (90%
plausibility range: 1700–5400) from our previous work in
which the model was specifically calibrated to data on
MSM [14]. Further research is required to model the
migrant population more accurately, to better estimate
incidence and number undiagnosed. Similarly, narrower
plausibility ranges may well also follow by modelling
subpopulations separately by reducing the realm to which
the model needs to fit the observed data.
In addition, our method of estimating the UK PLHIV
population is not easy to implement, requiring knowl-
edge of mathematical models and being computer
intensive. It should also be noted that our plausibility
ranges are wide as we take into account many sources of
error and variability. However, they are perhaps over-
estimated somewhat due to residual stochastic effects
relating to the fact that we model a random sample of the
infected population and scale up. Although generally,
more data should lead to less uncertainty, there is a limit to
how much the plausibility ranges can be reduced, given
that in this case, what we are trying to estimate is
intrinsically uncertain.
Achieving the UNAIDS 90–90–90 target requires
more than 73% of all PLHIV with an undetectable viral
load [34]. Even in the UK, where HIV services are
comprehensive and universally free, we estimate that only
62% of the PLHIV population have suppressed viral load.
In a previous modelling study, we showed that 90% of all
HIV-positive MSM would need to be suppressed to
achieve substantial reductions in incidence [9]. In most
settings, including the UK, the largest breakpoint in the
cascade is diagnosis, reiterating the importance of testing
[35]. It is recognized that late diagnosis, particularly among
heterosexuals, remains a problem in the UK [10]. There is
therefore a need for scaling-up access to HIV testing, and
frequency of testing in those at high risk, to reduce late
diagnoses and also undiagnosed HIV infection, which is
the likely reason for ongoing levels of high incidence.
It is possible with access to good surveillance data to
calculate the proportion of the diagnosed population who
are on ARTand the proportion of the treated population
who are virally suppressed. However, it is not possible to
know the size of the undiagnosed population without
some estimation method such as mathematical models or
prevalence surveys. The method presented and used here
allows calculation of such information which are vital to
know the extent to which targets such as those put in
place by UNAIDS are likely to be achieved. It is only
feasible to generate reliable estimates of the number of
PLHIV if good surveillance data are available however.
Our modelling work is based on extensive national-level
surveillance data, and though it would not be impossible
to do without all of it, a similarly strong set of data is
required for it to be applied in another setting.
In conclusion, we have presented a method to generate
national-level estimates about the size and characteristics
of HIV-positive populations incorporating migrants from
sub-Saharan Africa. These estimates should help inform
and evaluate current and future public health responses to
the epidemic by providing more information about the
affected population than can be understood and achieved
solely from surveillance.
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